GSK Targets Oncology Growth with $10.6 Billion Nuvalent Acquisition

A 40% premium on Nuvalent shares marks the largest acquisition for GSK in over a decade, signaling a decisive pivot toward cancer research. Under CEO Luke Miels, the British pharmaceutical giant is betting $10.6 billion that Nuvalent’s specialized pipeline will secure its future against looming patent expirations.

Editorial·June 9, 2026·reads: 1,461

GSK Targets Oncology Growth with $10.6 Billion Nuvalent Acquisition

The all-cash deal, priced at $124 per share, triggered an immediate 40% surge in Nuvalent’s stock during premarket trading, while GSK shares dipped 1.5% in London. By securing a firm foothold in precision lung cancer treatments, GSK aims to accelerate its late-stage development efforts. The acquisition, scheduled to close by the third quarter of 2026, relies on a combination of cash reserves and new debt facilities.

Analysts view the move as a necessary gamble to revitalize a pipeline facing intense competitive pressure. With the pharmaceutical landscape shifting, GSK is choosing to bypass organic growth hurdles by absorbing Nuvalent’s focused expertise. This capital deployment underscores a transition toward high-stakes oncology investment, prioritizing long-term revenue gains over immediate cost-cutting measures.